Elena's Movie Review Madness

Reviews from my 11-year old mind!

After the signing of the new agreement, Aerie sold more than $6 million to DSM and put $9 million on the table by the end of 2020. The expanded partnership also allows Aerie to access the preclinical implant of DSM latanoprost for people with glaucoma. Aerie paid DSM $6.0 million when the extended agreement was signed, an additional $9.0 million was paid to DSM by the end of 2020. Other payments to DSM depend on the fact that Aerie has passed several stages in clinical and regulatory development, and if products are marketed under this cooperation agreement, Aerie would also pay royalties to DSM. “This expanded agreement with DSM opens up many opportunities in Aerie as we continue to innovate with new drugs and technologies to potentially treat many eye diseases, well beyond our current priority of transferring AR-13503 to the clinic next year,” said Vicente Anido Jr., PhD, President and CEO of Aerie, in the press release. Aerie PharmaceuticalsMedia:Tad Heitmann, 949-526-8747theitmann@aeriepharma.comInvestments:Richard Rubino, 908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on behalf of Aerie PharmaceuticalsInvestors:Ami Bavishi, 212-213-0006abavishi@burnsmc.comordsmElizabeth Calvez, 973-257-8559elizabeth.calvez@dsm.com The new extended agreement with DSM grants Aerie an exclusive worldwide license for DSM polyesteramid polymer technology for an unlimited number of drugs in each ophthalmological indication. According to Aerie, the two companies plan to cooperate by the end of 2020. In July 2017, Aerie announced that it had entered into a research cooperation and licensing agreement with DSM to evaluate the sustainable supply of certain Aerie connections with DerSM bioeroable polyester polymer technology. Initially, the focus was on retinal diseases such as age-related wet macular degeneration (DMM) and diabetic macular edema (AMD). Promising preclinical results have been obtained with polyester amide implants, which contain AR-13503, a small winged preclinical molecule, and Aerie expects to submit a new study application in early 2019. In July 2017, Aerie announced that it had entered into a research cooperation and licensing agreement with DSM to evaluate the sustainable supply of certain Aerie connections with DerSM bioeroable polyester polymer technology. The focus was initially on retinal diseases such as wet AMD (age-related wet macular degeneration) and DME (diabetic macular edema).

Promising preclinical results have been obtained with polyester amide implants containing AR-13503, a small preclinical molecule clean aerie, and Aerie expects to submit an IND (Investigational New Drug) application in early 2019. AR-13503 inhibits rho-kinase and protein kinase C and therefore has the potential to respond to vascular dysfunction, fibrosis and inflammation in retinal disorders. If AR-13503 is formulated as a risk implant with DSM`s bioeramide polymer bio erodable technology, it can reduce the treatment load by allowing an intravitreal injection approximately every six months.

Categories: Uncategorized

Comments are closed.